JAMA (Journal of the American Medical Association)

Venous Thromboembolism Risk and Lipid-Lowering Therapy https://jamanetwork.com/journals/jamacardiology/fullarticle/2853339 To the Editor The post hoc analysis of the CLEAR Outcomes trial by Spiazzi and colleagues provides a clinically stimulating observation: bempedoic acid was associated with a 42% relative reduction in venous thromboembolism (VTE) among statin-intolerant patients at high cardiovascular risk or with established cardiovascular disease. This quantitative signal is particularly relevant because VTE, encompassing deep vein thrombosis and pulmonary embolism, remains a frequent and potentially severe condition, associated with substantial morbidity, mortality, recurrence, and health care burden.

Bleeding and Stroke Prevention After Left Atrial Appendage Occlusion https://jamanetwork.com/journals/jamacardiology/fullarticle/2853340 To the Editor Schmidt et al provide informative, long-term data on major bleeding (MB) after left atrial appendage occlusion (LAAO). However, several aspects merit further discussion in the context of the evolving use of LAAO and contemporary postprocedural management.

Left Atrial Systolic Collapse in Cardiac Tamponade https://jamanetwork.com/journals/jamacardiology/fullarticle/2853341 This case report discusses cardiac tamponade identified through left atrial collapse in a woman in her late 60s with a history of hypertension and diabetes who presented with progressive dyspnea and chest pain.

Vutrisiran and Transthyretin Amyloidosis With Cardiomyopathy https://jamanetwork.com/journals/jamacardiology/fullarticle/2853333 This post hoc analysis of a randomized clinical trial investigates the association of right ventricular (RV) function with clinical outcomes and evaluates the effect of vutrisiran on measures of RV function.

Inequities in Age-Related Perinatal Cardiometabolic Risk https://jamanetwork.com/journals/jamacardiology/fullarticle/2853335 This cross-sectional study quantifies disparities in age-related risk of perinatal cardiometabolic conditions at the intersection of race and ethnicity and socioeconomic status.

Left Atrial Appendage Occlusion vs Oral Anticoagulation—No Free Lunch https://jamanetwork.com/journals/jamacardiology/fullarticle/2853343 Atrial fibrillation (AF) is a leading cause of ischemic stroke. Moreover, strokes due to AF are more likely to have larger infarct volume, more frequent hemorrhagic transformation, and more severe disability and mortality. Oral anticoagulation (OAC) is recommended in individuals with AF who are at increased risk for stroke. Although OAC is highly effective at reducing the risk of stroke, adherence to OAC is challenging due to the risk of bleeding, adverse effects like bruising, and financial cost. Transesophageal echocardiography and autopsy data suggest that approximately 90% of embolic strokes in individuals with nonrheumatic AF are due to thrombi that originate in the left atrial appendage. Thus, in theory, percutaneous left atrial appendage occlusion (LAAO) should reduce the risk of ischemic stroke and reduce the risk of bleeding if patients can discontinue OAC. Yet as with any procedure, LAAO has risks, including procedural complications, incomplete seal, device-related thrombus, and a need for postprocedural antithrombotic therapy. The 2023 American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Clinical Pharmacy (ACCP)/Heart Rhythm Society (HRS) guidelines state that percutaneous LAAO may be a reasonable alternative to OAC based on patient preference in those with AF who have a high risk of major bleeding (class 2b).

Affiliations Updated https://jamanetwork.com/journals/jama/fullarticle/2853317 The Original Investigation titled “Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023,” published July 29, 2026, was corrected to update the author affiliations list. This article was corrected online.

Health Care Ownership and Patient Care https://jamanetwork.com/journals/jama/fullarticle/2853252 This Viewpoint discusses how consolidation in frontline care delivery has shaped health care markets across the US and how changes in ownership of hospitals and practices affect clinicians and patient outcomes.

Postural Orthostatic Tachycardia Syndrome https://jamanetwork.com/journals/jama/fullarticle/2853253 This review summarizes current evidence on pathophysiology, diagnosis, and management of postural orthostatic tachycardia syndrome (POTS).

Managing Chronic Subdural Hematoma—Reply https://jamanetwork.com/journals/jama/fullarticle/2853254 In Reply We thank Dr Madsbu and colleagues for their thoughtful comments regarding our trial and for highlighting the importance of optimizing surgical management in patients with chronic subdural hematoma.

Managing Chronic Subdural Hematoma https://jamanetwork.com/journals/jama/fullarticle/2853255 To the Editor Interest in embolization of the middle meningeal artery (EMMA) for chronic subdural hematoma is growing, and the trial by Dr Shankar and colleagues is welcome. The decision to randomize patients to adjuvant embolization after surgical drainage is commendable because it preserves blinding of the surgeon and isolates the effect of embolization from variability in surgical performance.

Rural-Urban Disparities in the Delivery and Intensity of the Medicare Hospice Benefit https://jamanetwork.com/journals/jama/fullarticle/2853256 This cross-sectional study examines how hospice care varies across the rural-urban continuum, including length of stay, care setting, visits by hospice staff, and rates of higher-level care.

Nonreporting of Race and Ethnicity in Medical Research Harms Us All https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852653 At JAMA Internal Medicine, we have become increasingly aware that some US researchers are unable to report on race or ethnicity as demographic variables to describe their sample or to conduct stratified analyses by these variables. In some cases, we have been informed that based on 3 recent US federal executive orders, the stewards of federal databases, such as those responsible for distributing data from the Centers for Medicaid and Medicare Services (CMS), are unable to release any race or ethnicity data for research purposes. The restrictions may be particularly prohibitive when study investigators are US federal employees. We have been informed of similar concerns occurring at other biomedical journals. The potential for restricted access to race and ethnicity data across many federal databases has been highlighted, with disruptions reported during 2025 at the Behavioral Risk Factor Surveillance System (BRFSS) and other Centers for Disease Control and Prevention (CDC) databases, the US Census database, Health and Human Services (HHS), and National Institutes of Health (NIH) public use databases.

Public Access to NIH-Funded Research Manuscripts https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852654 Health Care Policy

Error in References https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852655 The Viewpoint, “Scientific Writing, Generative Artificial Intelligence, and the Non–Native English Speaker,” published in JAMA Internal Medicine online on May 18, 2026, and in the July 2026 issue, included 2 erroneous references. The author has explained that both are genuine sources but that errors were introduced when a generative artificial intelligence tool was used for reformatting references and when the DOI (digital object identifier) of a different version of a conference document was updated manually. The article has been corrected.

TDP-43–Associated Neurodegenerative Disease https://jamanetwork.com/journals/jamaneurology/fullarticle/2853086 This narrative review discusses an alternative approach to disease classification based on underlying pathobiology, specifically examining the role of transactive response DNA-binding protein, 43 kDa (TDP-43), pathology in neurodegenerative disorders, paving the way for the development of biomarkers and the advancement of therapeutic candidates that effectively target fundamental disease mechanisms.

De Novo Aneurysm Risk After Aneurysmal Subarachnoid Hemorrhage in Young Survivors https://jamanetwork.com/journals/jamaneurology/fullarticle/2853087 This cohort study examines data across Swedish registries for young survivors of saccular aneurysmal subarachnoid hemorrhage to determine the lifetime cumulative incidence of, and factors associated with, radiologically detected de novo aneurysm formation.

Conceptual Recognition of TAND https://jamanetwork.com/journals/jamaneurology/fullarticle/2853088 The classification of neurodegenerative diseases increasingly incorporates underlying biology and pathology alongside clinical syndromes. This shift has been particularly evident in Alzheimer disease, where amyloid-β (Aβ) amyloid and tau biomarkers have changed both disease definitions and investigative methods. Similar developments have influenced the classification of other tauopathies and synucleinopathies. However, TAR DNA-binding protein 43 (TDP-43) proteinopathies present a difficult set of challenges, as TDP-43 pathology is observed in disorders that have traditionally been considered distinct clinical entities, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and inclusion body myositis (IBM). Although TDP-43 is well recognized as a major neurodegenerative proteinopathy, the issue raised by the term TDP-43–associated neurodegenerative disease (TAND) is whether a pathologic protein can represent an entire disease concept.

GLP-1 Drugs Linked to Lower Fracture Risk in People With Type 2 Diabetes https://jamanetwork.com/journals/jama/fullarticle/2853281 Glucagon-like peptide-1 (GLP-1) receptor agonists may be associated with a lower risk of fragility fracture in patients with type 2 diabetes, a study published in JAMA Network Open found.

FDA Approves First Freeze-Dried Plasma Product in the US https://jamanetwork.com/journals/jama/fullarticle/2853282 The US Food and Drug Administration (FDA) approved the nation’s first freeze-dried plasma product.